Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.